Maria Pribis
Optometrist · Stamford, CTNPI 1124252507
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (42.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Eyevance Pharmaceuticals LLC at 41.7% of the total. Reporting peaked in 2021 at $22,556 and has fallen 89.7% since, to $2,319 in 2025. Among optometrist clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 333 payments — averaging $234.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$33K
- Alcon$29K
- Oyster Point Pharma, Inc.$7K
- Novartis$2K
- Tarsus Pharmaceuticals, Inc.$2K
- Thea Pharma Inc.$989
- plus $5K from 16 others
What the payments were for
- Consulting fees$33,24342%
- Speaking & faculty fees$29,89838%
- Travel & lodging$7,4049%
- Food & beverage$7,68310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 67 | $32,604 |
| Alcon | 61 | $28,766 |
| Oyster Point Pharma, Inc. | 37 | $6,758 |
| Novartis | 10 | $2,271 |
| Tarsus Pharmaceuticals, Inc. | 17 | $1,993 |
| Thea Pharma Inc. | 4 | $989 |
| Dompe US, Inc. | 11 | $972 |
| Bausch & Lomb Americas Inc. | 23 | $878 |
| Shire North American Group Inc | 7 | $847 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $616 |
| Sun Pharmaceutical Industries Inc. | 17 | $426 |
| Harrow Eye, LLC | 13 | $265 |
| AbbVie(2 entities) | 9 | $181 |
| Coopervision Inc. | 9 | $155 |
| Sight Sciences, Inc. | 7 | $106 |
| Kala Pharmaceuticals, Inc. | 4 | $95 |
| Biotissue Holdings Inc. | 4 | $85 |
| Aerie Pharmaceuticals, Inc. | 4 | $75 |
| Rayner Intraocular Lenses Limited | 3 | $51 |
| Amgen | 2 | $44 |
| Johnson & Johnson Vision Care, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$16,580
- Zerviate$12,283
- Tobradex ST$9,828
- Flarex$9,828
- TYRVAYA$6,261
- DAILIES TOTAL1$4,767
- AIR OPTIX Aqua$3,900
- XIIDRA$3,233
- IYUZEH$952
- Precision 1$840
- XDEMVY$800
- Oxervate$750
- AIR OPTIX$568
- MIEBO$500
- TOTAL30$210
- INFUSE$125
- LOTEMAX SM$125
- CEQUA$124
How this compares
$78,227 in reported general payments places this provider in the 95th percentile of 574 optometrist providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $76,279 |
| XiidraLifitegrast | 24 | $40,919 |
| MieboPerfluorohexyloctane/Pf | 30 | $31,615 |
| XdemvyLotilaner | 13 | $23,694 |
| CequaCyclosporine | 23 | $20,393 |
| Cyclosporine | 16 | $11,639 |
| MoxifloxacinMoxifloxacin Hcl | 78 | $1,300 |
| Latanoprost | 76 | $1,063 |
| Brimonidine Tartrate | 22 | $852 |
| Timolol Maleate | 20 | $794 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 27 | $729 |
| Prednisolone Acetate | 28 | $679 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 28 | $278 |
| Dorzolamide Hcl | 11 | $271 |
| ErythromycinErythromycin Base | 30 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $181 | $76,27959 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $878 | $72,53454 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,993 | $23,69413 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $426 | $20,39323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 574 optometrist providers in Connecticut.
Other optometrist in Stamford
- Jesse ChinStamford$5K
- Joseph ThimonsFairfield$340K
- Inna LazarOld Greenwich$147K
- Jennifer StewartNew Canaan$91K
- Michael CooperWest Hartford$44K
- Joseph PavanoNew Britain$22K
- Susan JanikWest Hartford$20K
- Donald HigginsPlainville$18K
- Richard NowakEast Windsor$15K
- Barbara DuneHartford$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.